

Nucleus RadioPharma and BWXT Medical Enter Master Purchase and Supply Agreement for Critical Radiopharmaceutical Isotopes

Agreement Secures GMP-Grade Actinium-225 and Iodine-123 Supply to Support Growing Clinical Trial and Commercial Radiopharmaceutical Pipeline

ROCHESTER, MN June, 8th, 2026—Nucleus RadioPharma, Inc., a leading radiopharmaceutical CDMO, and BWXT Medical Ltd., a premier medical radioisotope producer, today announced the execution of a Master Purchase and Supply Agreement (MPSA). The agreement establishes a scalable, GMP-compliant supply framework for radiopharmaceutical isotopes to support Nucleus RadioPharma’s rapidly expanding clinical and commercial customer base.

Agreement Overview

Initial Product Schedules cover two isotopes central to today’s radiopharmaceutical pipeline.

1. Actinium-225 (Ac-225) Chloride Radiochemical, a high-purity alpha-emitting isotope driving targeted alpha therapy across oncology indications including metastatic prostate cancer, AML, and neuroendocrine tumors.
2. Iodine-123 (I-123) Sodium Iodide, a key diagnostic isotope enabling SPECT imaging and theranostic program support.

The MPSA framework allows for the phased addition of further isotopes as programs advance. BWXT Medical will maintain all Product Drug Master Files and provide letters of authorization to support clinical trial and marketing authorization submissions.


Supporting a Rapidly Expanding Clinical and Commercial Landscape

The radiopharmaceutical sector is at an inflection point. Following recent regulatory approvals of targeted therapies for prostate cancer and neuroendocrine tumors, a robust pipeline of alpha- and beta-emitting agents is advancing through clinical trials globally — with the market projected to exceed \$30 billion by the early 2030s. Reliable, clinical-grade Ac-225 supply has historically been a critical bottleneck for investigators.

By securing structured supply from BWXT Medical, one of few producers globally with the infrastructure to manufacture Ac-225 at scale, Nucleus RadioPharma is removing a key constraint for its pharmaceutical partners and ensuring they can meet accelerated development and commercial launch timelines.

For patients, this agreement has direct implications. Targeted alpha therapy offers highly localized, potent anti-tumor activity with the potential for meaningful disease control even in heavily





pre-treated populations. Structuring the supply chain needed to sustain clinical trials today is the pathway to commercial patient access tomorrow.

“Access to Actinium-225 and Iodine-123 at the quality and reliability that BWXT Medical provides is foundational to delivering on the promise of radiopharmaceutical therapy for cancer patients. As the clinical pipeline expands at a pace the industry has never seen, a structured, compliant, and scalable supply relationship is mission critical.”

— Jami Palumbo, Chief Technical Operations Officer, Nucleus RadioPharma, Inc.

About Nucleus RadioPharma, Inc.

Nucleus RadioPharma is an innovative CDMO dedicated to the development and manufacturing of targeted radiotherapies. With an emphasis on innovation and quality, Nucleus provides an array of services, from formulation and analytical development to regulatory documentation and drug product manufacturing. Its technology platforms are at the forefront of radiopharmaceutical research, designed to advance new therapies through clinical trials to commercialization. Learn more at <https://nucleusrad.com/>.

About BWXT Medical Ltd.

BWXT Medical Ltd., headquartered in Ottawa, Ontario, is a leading manufacturer of medical radioisotopes and radiopharmaceuticals. A subsidiary of BWX Technologies, Inc. (NYSE: BWXT), BWXT Medical operates production facilities in Ottawa and Vancouver, Canada, and supplies a broad portfolio of diagnostic and therapeutic isotopes to customers around the world. The company’s products are manufactured to GMP standards and used in nuclear medicine imaging and targeted radionuclide therapy across a wide range of clinical indications.

For more information, please contact:

Nucleus RadioPharma

or

Chad Crookshanks

BD@nucleusrad.com

Sr. Director, Marketing & Communications

ccrookshanks@nucleusrad.com

